Detalhe da pesquisa
1.
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kidney Int
; 104(6): 1219-1226, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657768
2.
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Cardiovasc Diabetol
; 22(1): 251, 2023 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716952
3.
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Curr Opin Nephrol Hypertens
; 30(4): 456-465, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990507
4.
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
Diabetes Obes Metab
; 25(8): 2419-2422, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37157922
5.
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
Clin Pharmacol Ther
; 112(5): 1098-1107, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892316
6.
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
JACC Heart Fail
; 10(7): 498-507, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772861